ADCETRIS® (brentuximab vedotin) as a treatment option for your adult patients with systemic anaplastic large cell lymphoma
ADCETRIS is indicated for use in systemic anaplastic large cell lymphoma (sALCL) for:1
- Adult patients with previously untreated sALCL in combination with cyclophosphamide, doxorubicin and prednisone (CHP)
- Adult patients with relapsed or refractory sALCL
Funding status
ADCETRIS is NICE recommended in combination with CHP as an option for the treatment of adult patients with untreated sALCL.2 ADCETRIS is also NICE recommended as a monotherapy option for treating relapsed or refractory sALCL in adult patients, providing they have an ECOG performance status of 0 or 1.3*†
For more information on NHS funding of ADCETRIS, please refer to the Blueteq criteria where applicable.4
ADCETRIS is accepted for use in NHS Scotland in combination with CHP for adults with previously untreated sALCL, where applicable.5
*NHS Blueteq criteria state that ECOG performance status 0, 1, or 2 is valid for treatment4
† When assessing ECOG performance status, physical, sensory or learning disabilities, or communication difficulties should be taken into account and adjusted for.3
ADCETRIS key safety information
Please consult the Summary of Product Characteristics before prescribing ADCETRIS and for full information about dosing, administration, contraindications, special warnings and tolerability profile.
When used as monotherapy (across HL, sALCL and CTCL studies), the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, neutropenia, upper respiratory tract infection, arthralgia, rash, cough, vomiting, pruritus, peripheral motor neuropathy, infusion-related reactions, constipation, dyspnoea, myalgia, weight decreased, and abdominal pain.1
When used in combination therapy with AVD (in previously untreated stage 3 or 4 HL) and CHP (in previously untreated sALCL), the most frequent adverse reactions (≥10%) were infections, neutropenia, peripheral sensory neuropathy, nausea, constipation, vomiting, diarrhoea, fatigue, pyrexia, alopecia, anaemia, weight decreased, stomatitis, febrile neutropenia, abdominal pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnoea, arthralgia, myalgia, back pain, peripheral motor neuropathy, upper respiratory tract infection, and dizziness.1
Further information
Click here for key data supporting the safety and efficacy of ADCETRIS in combination with CHP for adult patients with previously untreated sALCL.
CHP, cyclophosphamide, doxorubicin, and prednisone; ECOG, Eastern Cooperative Oncology Group; NICE, National Institute for Health and Care Excellence; sALCL, systemic anaplastic large cell lymphoma; SMC, Scottish Medicines Consortium.
1. ADCETRIS Summary of Product Characteristics; 2. NICE TA641. Available at: www.nice.org.uk/guidance/ta641/chapter/1-Recommendation; 3. NICE TA478. Available at: www.nice.org.uk/guidance/ta478/chapter/1-Recommendation; 4. Cancer Drugs Fund List. Available at: https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/. 5. SMC 2310. Available at: scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-full-smc2310/.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
